Christina Weng, MD
|
Qing Yu Christina Weng, MD is a physician-scientist, entrepreneur, and biotech
executive. As an attending dermatologist at the Massachusetts General Hospital and Instructor in Dermatology at Harvard Medical School, she specializes in melanoma and pigmentary disorders. She is the Senior Medical Director of Kira Pharmaceuticals, a Boston-based global biotech company developing innovative complement therapeutics. Dr. Weng also co-founded Mymiel, a high-performance clean skincare line, where she is the Chief Strategy Officer. She serves on the Board of Directors for the Dermatology Innovation Forum and the Dermatology Summit. Dr. Weng attended the California Institute of Technology, where she received her bachelor's degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH. Dr. Weng’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Her work additionally explores strategies for cutaneous drug delivery. Dr. Weng’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research grants and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health. She holds one U.S. patent. Dr. Weng is also a regularly quoted medical expert on the topics of skincare and cosmetics, with press appearances in Tatler, Allure, The Huffington Post, and numerous other media publications |
